中华乳腺病杂志（电子版）
中華乳腺病雜誌（電子版）
중화유선병잡지（전자판）
CHINESE JOURNAL OF BREAST DISEASE(ELECTRONIC VERSION)
2009年
4期
387-397
,共11页
王佳妮%刘仁斌%Mohamed Abdalwali·Thabit%梁惠珍%吴壮宏%张文辉
王佳妮%劉仁斌%Mohamed Abdalwali·Thabit%樑惠珍%吳壯宏%張文輝
왕가니%류인빈%Mohamed Abdalwali·Thabit%량혜진%오장굉%장문휘
乳腺肿瘤%雌激素受体α%雌激素受体β%雌激素受体β1%雌激素受体βcx
乳腺腫瘤%雌激素受體α%雌激素受體β%雌激素受體β1%雌激素受體βcx
유선종류%자격소수체α%자격소수체β%자격소수체β1%자격소수체βcx
Breast neoplasms%Estrogen Receptor α%Estrogen Receptor β%Estrogen Receptor β1%Estrogen Receptor βcx
目的 探讨雌激素受体β(Erβ)及其异构体(ERβ1、Erβcx)在人类表皮生长因子受体2(HER-2)阳性与阴性乳腺癌组织中的表达差异,分析其与雌激素受体α(Erα)、孕激素受体(PR)表达及临床分期和腋窝淋巴结状况的关系.方法 采用简单随机抽样的方法选择中山大学附属第一医院2004年12月至2007年12月收治的HER-2高表达(Ⅲ)51例与无表达(-)53例乳腺浸润性导管癌病例,分别检测乳腺癌组织的Erα、Erβ、ERβ1、Erβcx及PR表达水平,分析其相互关系及与肿瘤临床分期、腋窝淋巴结转移等临床指标的相关性.采用χ2检验对HER-2(Ⅲ)组与(-)组淋巴结表达情况进行对比分析,采用wilcoxon秩和检验对HER-2(Ⅲ)组与(-)组的临床分期及Erα、Erβ、ERβ1、Erβcx 、PR表达进行对比分析,对HER-2(Ⅲ)及HER-2(-)组内各指标采用Spearman相关性分析.结果 在HER-2(Ⅲ)与(-)两组中临床分期及淋巴结转移率差异均无统计学意义(P>0.050);HER-2(-)组Erα、Erβ、ERβ1、Erβcx 、PR的阳性表达率均低于HER-2(-)组,差异均有统计学意义(P<0.050).HER-2(-)组中,ERβ1与Erα的表达、Erβcx与PR的表达均呈正相关(P<0.050),但Erβ、ERβ1及Erβcx均未显示与淋巴结转移状况及临床分期相关(P>0.050). HER-2(-)组中,ERβ1及Erβcx的表达均与 Erα、Erβ、PR呈正相关(P<0.050),但Erα、PR、Erβ、ERβ1及Erβcx 均与淋巴结转移情况及临床分期无显著相关性(P>0.050).结论 ERβ1和Erβcx可能作为乳腺癌预后良好的指标,有必要进一步研究其与乳腺癌治疗后的生存关系.
目的 探討雌激素受體β(Erβ)及其異構體(ERβ1、Erβcx)在人類錶皮生長因子受體2(HER-2)暘性與陰性乳腺癌組織中的錶達差異,分析其與雌激素受體α(Erα)、孕激素受體(PR)錶達及臨床分期和腋窩淋巴結狀況的關繫.方法 採用簡單隨機抽樣的方法選擇中山大學附屬第一醫院2004年12月至2007年12月收治的HER-2高錶達(Ⅲ)51例與無錶達(-)53例乳腺浸潤性導管癌病例,分彆檢測乳腺癌組織的Erα、Erβ、ERβ1、Erβcx及PR錶達水平,分析其相互關繫及與腫瘤臨床分期、腋窩淋巴結轉移等臨床指標的相關性.採用χ2檢驗對HER-2(Ⅲ)組與(-)組淋巴結錶達情況進行對比分析,採用wilcoxon秩和檢驗對HER-2(Ⅲ)組與(-)組的臨床分期及Erα、Erβ、ERβ1、Erβcx 、PR錶達進行對比分析,對HER-2(Ⅲ)及HER-2(-)組內各指標採用Spearman相關性分析.結果 在HER-2(Ⅲ)與(-)兩組中臨床分期及淋巴結轉移率差異均無統計學意義(P>0.050);HER-2(-)組Erα、Erβ、ERβ1、Erβcx 、PR的暘性錶達率均低于HER-2(-)組,差異均有統計學意義(P<0.050).HER-2(-)組中,ERβ1與Erα的錶達、Erβcx與PR的錶達均呈正相關(P<0.050),但Erβ、ERβ1及Erβcx均未顯示與淋巴結轉移狀況及臨床分期相關(P>0.050). HER-2(-)組中,ERβ1及Erβcx的錶達均與 Erα、Erβ、PR呈正相關(P<0.050),但Erα、PR、Erβ、ERβ1及Erβcx 均與淋巴結轉移情況及臨床分期無顯著相關性(P>0.050).結論 ERβ1和Erβcx可能作為乳腺癌預後良好的指標,有必要進一步研究其與乳腺癌治療後的生存關繫.
목적 탐토자격소수체β(Erβ)급기이구체(ERβ1、Erβcx)재인류표피생장인자수체2(HER-2)양성여음성유선암조직중적표체차이,분석기여자격소수체α(Erα)、잉격소수체(PR)표체급림상분기화액와림파결상황적관계.방법 채용간단수궤추양적방법선택중산대학부속제일의원2004년12월지2007년12월수치적HER-2고표체(Ⅲ)51례여무표체(-)53례유선침윤성도관암병례,분별검측유선암조직적Erα、Erβ、ERβ1、Erβcx급PR표체수평,분석기상호관계급여종류림상분기、액와림파결전이등림상지표적상관성.채용χ2검험대HER-2(Ⅲ)조여(-)조림파결표체정황진행대비분석,채용wilcoxon질화검험대HER-2(Ⅲ)조여(-)조적림상분기급Erα、Erβ、ERβ1、Erβcx 、PR표체진행대비분석,대HER-2(Ⅲ)급HER-2(-)조내각지표채용Spearman상관성분석.결과 재HER-2(Ⅲ)여(-)량조중림상분기급림파결전이솔차이균무통계학의의(P>0.050);HER-2(-)조Erα、Erβ、ERβ1、Erβcx 、PR적양성표체솔균저우HER-2(-)조,차이균유통계학의의(P<0.050).HER-2(-)조중,ERβ1여Erα적표체、Erβcx여PR적표체균정정상관(P<0.050),단Erβ、ERβ1급Erβcx균미현시여림파결전이상황급림상분기상관(P>0.050). HER-2(-)조중,ERβ1급Erβcx적표체균여 Erα、Erβ、PR정정상관(P<0.050),단Erα、PR、Erβ、ERβ1급Erβcx 균여림파결전이정황급림상분기무현저상관성(P>0.050).결론 ERβ1화Erβcx가능작위유선암예후량호적지표,유필요진일보연구기여유선암치료후적생존관계.
Objective To investigate the difference in the expressions of estrogen receptor β (Erβ), and its variants ERβ1 and Erβcx in human epithelial growth factor receptor 2 (HER-2) positive and negative breast cancer, and analyze the expressions of estrogen receptorα(Erα)and progesterone receptor (PR), and their association with clinical stage and axillary lymph node status.Methods Group sequential design and simple
random sampling were used for the study. From Dec 2004 to Dec 2007, 51 cases of HER-2 (Ⅲ)and 53 cases of HER-2 (-) breast invasive ductal carcinoma were randomly selected from the First Affiliated Hospital of Sun Yat-sen University to separately detect the expressions of Erα, Erβ, ERβ1 and Erβcx and PR in breast cancer, and analyze their relationships with TNM stage and axillary lymph node metastases,and then analyze the lymph node status of the HER-2 (Ⅲ) group and the HER-2 (-) group using
Chi-square test, analyze the TNM stage and the expressions of Erα, PR, Erβ, ERβ1 and Erβcx of HER-2 (Ⅲ) and HER-2 (-) groups using Wilcoxon rank sum test. The relationship of these index in the two groups were analyzed by Spearman rank correlation respectively.Results The positive rate of lymph node metastases in both the HER-2(Ⅲ) and HER-2 (-) patients had no significant difference. In both the HER-2 (Ⅲ) and HER-2 (-) groups there were no statistical differences in clinical stage and axillary lymph node metastasis (P>0.0500. In the HER-2(Ⅲ)group the positive expression rates of Erα, Erβ, ERβ1 , Erβcx and PR were lower than in the HER-2 (-) group, with statistically significant differences between the two groups(P<0.050). In the HER-2 (Ⅲ) group, the expression of ERβ1 was positively correlated with Erα, and Erβcx expression was positively correlated with PR (P<0.050), but Erβ, ERβ1 and Erβcx were found irrelevant with TNM stages and axillary lymph node metastasis (P>0.050). In the HER-2 (-) group, the expressions of ERβ1 and Erβcx were both positively correlated with Erβ, Erα and PR (P<0.050). Erα, PR, Erβ, ERβ1 and Erβcx were all irrelevant with TNM stages and axillary lymph node
metastasis(P>0.050).Conclusion ERβ1 and Erβcx could be considered as favorable prognostic markers of breast cancer. Further study is needed to explore their correlation with survival of breast cancer patients after treatment.
